BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
Pre-Launchbuprenorphine hydrochloride; naloxone hydrochloride
ANDABUCCAL, SUBLINGUALFILM
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE (buprenorphine hydrochloride; naloxone hydrochloride) by Teva is naloxone.
Drug data last refreshed 1mo ago
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Teva
Israel - Petach Tikva
Worked on BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.